This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts

Ophthalmology Risk Minimisation Materials

EYLEA® (aflibercept)

Close-up-eye

Here you can find links to the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for

EYLEA® (aflibercept)
, via the Electronics Medicines Compendium (eMC), a resource providing information about all medicines available in the UK. Please note that this information is specific to the United Kingdom and is not intended to replace the advice of a qualified doctor. For more information on EYLEA or any related support, please contact the Bayer Medical Information team on
0118 206 3116
, or email medical.information@bayer.co.uk.

 

EYLEA 8 mg Summary of Product Characteristics

EYLEA 8 mg Patient Information Leaflet

 

EYLEA 2 mg Summary of Product Characteristics

EYLEA 2 mg Patient Information Leaflet

Prescriber guide PDF thumbnail
EYLEA® (aflibercept)

Prescriber Guide

Download

EYLEA Prescriber Guide Video

Prescribing information for EYLEA® (aflibercept)

can be found here
.

EYLEA Patient Guides

All patient guides are recertified for use with original date of preparation.

Your guide to EYLEA_wAMD thumbnail
Your guide to EYLEA

Wet age-related macular degeneration (wAMD)

Download

Abbreviations

BRVO, branch retinal vein occlusion. CRVO, central retinal vein occlusion. DMO, diabetic macular oedema. mCNV, myopic choroidal neovascularisation. ROP, retinopathy of prematurity. wAMD, wet age-related macular degeneration.

Prescribing information for EYLEA® (aflibercept)

can be found here
.

EYLEA 8 mg logo
EYLEA® (aflibercept) 8 mg
Discover data and resources about EYLEA 8 mg
PP-EYL-GB-3129, March 2026
RWE page content card
Real World Experience
Practical insights into the experiences of clinicians implementing treatment with EYLEA® (aflibercept) 8 mg in the UK
PP-EYL-GB-3143, April 2026
EYLEA 2 mg
EYLEA® (aflibercept) 2 mg
Discover data and resources about EYLEA 2 mg
PP-EYL-GB-2793, March 2025

PP-EYL-GB-3151 | May 2026